Life Technologies, Suzhou Ribo deal

Life Technologies granted Suzhou Ribo exclusive rights to use Invivofectamine Rx delivery technology to develop small interfering RNA (siRNA) therapeutics in China. The first program will focus on HBV infection. Life Tech is eligible to receive undisclosed milestones plus royalties for each product developed under the deal. Invivofectamine Rx uses an undisclosed chemical structure to increase potency and decrease toxicity of RNAi compounds, which are delivered in vivo into liver cells. Suzhou Ribo develops nucleic acid drugs and products based on RNAi technology for the Chinese market. The companies declined to disclose details. ...